Prevalence of resistant hypertension in 1810 patients followed up in a specialized outpatient clinic and its association with the metabolic syndrome

Blood Pressure

Volumn 22, Issue 5, 2013, Pages 307-311

  Tziomalos, Konstantinos ^a   Kirkineska, Lambrini ^a   Baltatzi, Maria ^a   Efthymiou, Elias ^a   Psianou, Konstantia ^a   Papastergiou, Natalia ^a   Magkou, Dimitra ^a   Zervopoulos, Georgios ^a   Kagelidis, Giannis ^a   Karlafti, Eleni ^a   Savopoulos, Christos ^a   Hatzitolios, Apostolos I ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Chronic kidney disease; Metabolic syndrome; Obesity; Resistant hypertension; Type 2 diabetes mellitus

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METABOLIC SYNDROME X; OBESITY; OUTPATIENT DEPARTMENT; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION;

AMBULATORY CARE FACILITIES; BODY MASS INDEX; FEMALE; GREECE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 84884685620     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2013.765632     Document Type: Article

References (25)

1. Calhoun DA, Jones D, Textor S, Goff D C, Murphy TP, Toto RD, et al. American Heart Association Professional Education Committee. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientifi c statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117: E510-e526
2. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005; 18: 1422-1428
3. Persell SD. P revalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011; 57: 1076-1080
4. De La Sierra A, Segura J, Banegas JR, Gorostidi M, De La Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classifi ed on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 898-902
5. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002; 4: 393-404
6. Gupta AK, Nasothimiou E G, Chang C L, Sever PS, Dahl öf B, Poulter NR. ASCOT investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): A risk score to identify those at high-risk. J Hypertens. 2011; 29: 2004-2013
7. Sarafi dis PA, Bakris GL. R esistant hypertension: An overview of evaluation and treatment. J Am Coll Cardiol. 2008; 52: 1749-1757
8. Fagard RH. R esistant hypertension. H eart. 2012; 9 8: 254-261
9. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. R USH University Hypertension Service. Resistant hypertension revisited: A comparison of two university-based cohorts. Am J Hypertens. 2005; 18: 619-626
10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105-1187
11. Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular fi ltration rate from serum creatinine: A new prediction equation. Modifi cation of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470
13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/ National Heart, Lung, and Blood Institute Scientifi c Statement. Circulation. 2005; 112: 2735-2752
14. Grundy SM. M etabolic syndrome pandemic. A rterioscler Thromb Vasc Biol. 2008; 28: 629-636
15. ForDeS, Giles WH, Mokdad A H. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care. 2004; 27: 2444-2449
16. Athyros V G, Ganotakis E S, Tziomalos K, Papageorgiou AA, Anagnostis P, Griva T, et al. Comparison of four defi nitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin. 2010; 26: 713-719
17. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-Analysis. J Am Coll Cardiol. 2010; 56: 1113-1132
18. Athyros VG, Karagiannis A, Hatzitolios A I, Paletas K, Savopoulos C, Giannoglou G, et al. SAGE-METS collaborative group. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: The SAGE-METS study. Curr Med Res Opin. 2009; 25: 971-980
19. Cornier MA, Dabelea D, Hernandez T L, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. 2008; 29: 777-822
20. Chen J, Muntner P, Hamm L L, Jones D W, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004; 140: 167-174
21. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis. 2010; 20: 140-146
22. Hatzitolios A, Iliadis F, Katsiki N, Baltatzi M. I s the antihypertensive effect of dietary supplements via aldehydes reduction evidence based? A systematic review. Clin Exp Hypertens. 2008; 30: 628-639
23. Baltatzi M, Hatzitolios A, Tziomalos K, Iliadis F, Zamboulis Ch. Neuropeptide Y and alpha-melanocyte-stimulating hormone: Interaction in obesity and possible role in the development of hypertension. Int J Clin Pract. 2008; 62: 1432-1440
24. Baltatzi M, Katsiki N, Savopoulos C, Iliadis F, Koliakos G, Hatzitolios AI. Plasma neuropeptide Y (NPY) and alphamelanocyte stimulating hormone (a-MSH) levels in patients with or without hypertension and/or obesity: A pilot study. Am J Cardiovasc Dis. 2011; 1: 48-59
25. Karagiannis A, Hatzitolios AI, Athyros V G, Deligianni K, Charalambous C, Papathanakis C, et al. Implementation of guidelines for the management of arterial hypertension. The IMPULSION study. Open Cardiovasc Med J. 2009; 3: 26-34